Qed Therapeutics Is A Biopharmaceutical Company Based In Palo Altocaliforniaand An Affiliate Of Bridgebio Pharmathe Company Focuses On Precision Medicine For Diseases Driven By Fibroblast Growth Factor Receptorsfgfrand Skeletal Dysplasiasqed Is Dedicated To Developing Therapies For Rare Genetic Conditionsparticularly Targeting Disorders Like Achondroplasia And Hypochondroplasia One Of Their Key Products Is Infigratinibbgj398 An Orally Administered Fgfr1 3 Tyrosine Kinase Inhibitorthis Drug Has Shown Clinical Efficacy In Treating Chemotherapy Refractory Cholangiocarcinoma And Advanced Urothelial Carcinomaqed Is Actively Involved In Clinical Studies To Evaluate Infigratinib S Effectiveness In Addressing Abnormal Bone Growth Associated With Fgfr3 Signaling Dysregulationthe Company Has A Robust Pipeline With Over 30 Development Programs Focused On Fgfr Related Genetic Diseases And Cancers Qed Therapeutics Is Committed To Engaging With Patientsfamiliesand Healthcare Providers To Ensure Their Research Aligns With Community Needsthey Advocate For Improved Standards In Managing Skeletal Dysplasias And Aim To Deliver Innovative Therapies That Address Unmet Medical Needs
No conferences found for this company.
| Company Name | Qed Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
